(Q43832882)

27 November 2017

title

Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16. (English)

1 reference

27 November 2017

1 reference

Lewis M Slater

1

1 reference

27 November 2017

Marie Stupecky

series ordinal

2

1 reference

27 November 2017

Paula Sweet

series ordinal

3

1 reference

27 November 2017

Kathryn E Osann

series ordinal

4

1 reference

27 November 2017

publication date

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

26

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

203-206

1 reference

Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900105-9

7 January 2021

Shifting the cancer paradigm: must we kill to cure?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900105-9

7 January 2021

Elimination of EL-4 and L1210 murine tumors by 1,3-bis (2-chloroethyl)-1-nitrosourea requires an intact immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900105-9

7 January 2021

Thymus and autoimmunity. Transplantation of the thymus from cyclosporin A-treated mice causes organ-specific autoimmune disease in athymic nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900105-9

7 January 2021

10.1016/S0145-2126(01)00105-9

Identifiers

DOI

1 reference

27 November 2017

1 reference